Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.
Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.
LSP, which has raised more than €1bn since its inception 25 years ago, has provided start-up and growth capital to...
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Swiss major confident that new oncology drugs will fill revenue gap.
Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
